Dyax and ZymoGenetics Enter Into Library License Agreement
Complete the form below to unlock access to ALL audio articles.
Dyax Corp. has announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to ZymoGenetics, Inc. for the discovery of therapeutic antibodies.
This collaboration with ZymoGenetics is part of Dyax’s Licensing and Funded Research Program (LFRP) partnered with Paul Royalty Fund.
Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from ZymoGenetics’s use of the Dyax libraries.
The agreement provides ZymoGenetics a license to Dyax’s antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s antibody phage display technology.
Commented Henry E. Blair, Chairman and Chief Executive Officer of Dyax, "We are very excited about this library license agreement with ZymoGenetics, a company dedicated to the development of protein drug therapeutics, as we continue to grow our extensive portfolio of licensees."
"Our committed business development team has been successful in actively building Dyax’s Licensing and Funded Research Program which allows us to generate near-term revenue as well as potential milestones and royalties on future products."
